A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2011
11/17/2011	US20110281838 5-alkynyl-pyrimidines
11/17/2011	US20110281832 Organic compounds
11/17/2011	US20110281829 Novel composition
11/17/2011	US20110281822 Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity
11/17/2011	US20110281821 Modulators of Mitotic Kinases
11/17/2011	US20110281815 Parental formulations of gemcitabine derivatives
11/17/2011	US20110281814 Methods and compositions for treating breast cancer
11/17/2011	US20110281813 Method of treating c-kit positive relapsed acute myeloid leukemia
11/17/2011	US20110281804 Peptidic and peptidomimetic compounds for regulating autophagy
11/17/2011	US20110281803 Sulfatase enzymes
11/17/2011	US20110281796 Novel activin receptor and uses thereof
11/17/2011	US20110281789 Ulbp antibodies
11/17/2011	US20110281787 Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
11/17/2011	US20110281292 Compositions and methods for identifying antigens which elicit an immune response
11/17/2011	US20110280975 Composition comprising bamboo extract and the compounds isolated therefrom showing activity for the treatment and prevention of inflammatory and blood circulation disease
11/17/2011	US20110280974 Substances Having Body Mass Redistribution Properties
11/17/2011	US20110280963 Combination therapy for the treatment of cancer
11/17/2011	US20110280951 Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
11/17/2011	US20110280940 Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy
11/17/2011	US20110280934 Increased Expression of Specific Antigens
11/17/2011	US20110280932 Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent
11/17/2011	US20110280931 Matrix metalloproteinase inhibitor
11/17/2011	US20110280930 Products and methods for stimulating an immune response
11/17/2011	US20110280929 Sirna of nf-kb p105 for inhibiting cell proliferation and migration and a composition comprising same
11/17/2011	US20110280911 Cancer vaccine compositions and methods of using the same
11/17/2011	US20110280909 Method and system for effecting changes in pigmented tissue
11/17/2011	US20110280908 Multimeric protein toxins to target cells having multiple identifying characteristics
11/17/2011	US20110280906 Method for augmenting the immunogenicity of an antigen
11/17/2011	US20110280903 Immunostimulatory combinations
11/17/2011	US20110280899 Novel Immunogenic Lipopeptides Comprising T-Helper And Cytotoxic T-Lymphocyte (CTL) Epitopes
11/17/2011	US20110280898 Inhbb epitope peptides and vaccines containing the same
11/17/2011	US20110280897 Polypeptides and uses thereof
11/17/2011	US20110280896 Methods and compositions for tumor vaccination and therapy
11/17/2011	US20110280894 Her2/neu specific t cell receptors
11/17/2011	US20110280892 Toxin conjugated eph receptor antibodies
11/17/2011	US20110280891 Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
11/17/2011	US20110280890 Prodrugs of cc-1065 analogs
11/17/2011	US20110280889 High affinity t cell receptor and use thereof
11/17/2011	US20110280888 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
11/17/2011	US20110280886 Treating cancer by modulating mnk
11/17/2011	US20110280885 Cancer immunotherapy
11/17/2011	US20110280884 Anti-cd98 antibody
11/17/2011	US20110280883 Fully human anti-epidermal growth factor receptor antibodies
11/17/2011	US20110280881 Novel anti-hsp90 monoclonal antibody
11/17/2011	US20110280877 Inhibition of B7-H1/CD80 interaction and uses thereof
11/17/2011	US20110280876 Mutated netrin - 4, fragments thereof and their use as medicines
11/17/2011	US20110280875 Antibodies which bind human cxcr3
11/17/2011	US20110280874 Modulating angiogenesis
11/17/2011	US20110280873 MCP1-Ig FUSION VARIANTS
11/17/2011	US20110280870 Hepatocyte growth factor receptor antagonists and uses thereof
11/17/2011	US20110280868 Methods of preventing or treating t cell malignancies by administering anti-cd2 antagonists
11/17/2011	US20110280866 Anti-cd 160 monoclonal antibodies and uses thereof
11/17/2011	US20110280861 Method for mir-125a in promoting hematopoietic stem cell self renewal and expansion
11/17/2011	US20110280860 Pharmaceutical compositions comprising monoterpenes
11/17/2011	US20110280849 Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
11/17/2011	US20110280836 Compositions for bacterial mediated gene silencing and methods of using the same
11/17/2011	US20110280831 Combinations comprising methotrexate and dhodh inhibitors
11/17/2011	US20110280830 Albumin Fusion Proteins
11/17/2011	US20110280829 Low Molecular Weight Sulphated Polysaccharides as Candidates for Anti-Angiogenic Therapy
11/17/2011	US20110280827 Methods and compositions for treating hematological malignancies
11/17/2011	US20110280826 Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof
11/17/2011	US20110280809 Pdia4, target of cytopiloyne derivatives, for tumor diagnosis and treatment
11/17/2011	US20110280799 Nanocells for diagnosis and treatment of diseases and disorders
11/17/2011	DE102010023850A1 New nanoparticles comprising a core, a protective shell that covers the core, and heme- and hemin molecules covalently bonded to the protective shell or the core, useful as dietary supplement and for treating iron deficiency and cancer
11/17/2011	CA2835596A1 Benzo- or pyrido-imidazole derivative
11/17/2011	CA2800497A1 Ratiometric combinatorial drug delivery
11/17/2011	CA2800311A1 Anti-fgfr2 antibodies
11/17/2011	CA2799495A1 Pyrimidine compounds that inhibit anaplastic lymphoma kinase
11/17/2011	CA2799468A1 Functional, cross-linked nanostructures for tandem optical imaging and therapy
11/17/2011	CA2799431A1 Cancer prevention and treatment methods based on dietary polyamine content
11/17/2011	CA2799420A1 Compositions and methods for treating neoplasia, inflammatory disease and other disorders
11/17/2011	CA2799403A1 Compositions and methods for treating leukemia
11/17/2011	CA2799177A1 Enhanced death receptor agonists
11/17/2011	CA2799156A1 Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases
11/17/2011	CA2799154A1 Indazole inhibitors of kinase
11/17/2011	CA2799146A1 Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine
11/17/2011	CA2798932A1 The n-domain of carcinoembryonic antigen and compositions, methods and uses thereof
11/17/2011	CA2798856A1 Immunostimulatory and vaccine compositions
11/17/2011	CA2798763A1 Compounds useful as inhibitors of atr kinase
11/17/2011	CA2798760A1 2-aminopyridine derivatives useful as inhibitors of atr kinase
11/17/2011	CA2798375A1 Substituted heterocyclyl benzyl pyrazoles, and use thereof
11/17/2011	CA2790847A1 Fused bicyclic kinase inhibitors
11/16/2011	EP2386859A2 Diagnostic tumor markers
11/16/2011	EP2386640A2 Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
11/16/2011	EP2386639A2 Modified pore-forming protein toxins and use thereof
11/16/2011	EP2386637A2 MicroRNA molecules
11/16/2011	EP2386630A1 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
11/16/2011	EP2386629A1 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
11/16/2011	EP2386574A2 Polypeptide variants with altered effector function
11/16/2011	EP2386565A2 Compounds and methods to inhibit or augment an inflammatory response
11/16/2011	EP2386559A1 Cytotoxiv agents comprising new tomaymycin derivatives and their therapeutic use
11/16/2011	EP2386557A1 Novel substituted imidazoquinolines
11/16/2011	EP2386551A1 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
11/16/2011	EP2386550A1 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
11/16/2011	EP2386545A1 Heteroaryl ureas containing nitrogen hetero-atoms as P38 kinase inhibitors
11/16/2011	EP2386543A1 3-Z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
11/16/2011	EP2386542A1 Diindolylmethane and c-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
11/16/2011	EP2386319A1 Promoters exhibiting endothelial cell specificity and methods of using same
11/16/2011	EP2386312A2 Intrathecal and intratumoral superantigens to treat malignant disease
11/16/2011	EP2386305A2 Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues

1 ... 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 ... 2211